{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T16:42:11Z","timestamp":1648572131529},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,2,17]],"date-time":"2016-02-17T00:00:00Z","timestamp":1455667200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00108-016-0017-y","type":"journal-article","created":{"date-parts":[[2016,2,17]],"date-time":"2016-02-17T09:01:17Z","timestamp":1455699677000},"page":"230-237","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aktuelle Therapiestrategien beim Mantelzelllymphom"],"prefix":"10.1007","volume":"57","author":[{"given":"M.","family":"Dreyling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schnaiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Hoster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,17]]},"reference":[{"key":"17_CR1","first-page":"\u25a0","volume":"\u25a0","author":"E Hoster","year":"2015","unstructured":"Hoster E, Rosenwald A, Berger F et al (2015) Prognostic value of Ki-67 index, cytology, and growth pattern in mantle cell Lymphoma: results from randomized trials of the european MCL network. J Clin Oncol (im Druck)","journal-title":"J Clin Oncol"},{"key":"17_CR2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL et al (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4.\u00a0Aufl. International Agency for Research on Cancer, Lyon","edition":"4"},{"issue":"Suppl 3","key":"17_CR3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/annonc\/mdu264","volume":"25","author":"M Dreyling","year":"2014","unstructured":"Dreyling M, Geisler C, Hermine O et al (2014) Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):83\u201389","journal-title":"Ann Oncol"},{"key":"17_CR4","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","volume":"27","author":"P Martin","year":"2009","unstructured":"Martin P, Chadburn A, Christos P et al (2009) Outcome of deferred initial therapy in mantle-cell Lymphoma. J Clin Oncol 27:1209\u20131213","journal-title":"J Clin Oncol"},{"key":"17_CR5","unstructured":"DGHO Leitlinien Mantelzelllymphom. www.onkopedia.com\/de\/onkopedia\/guidelines\/mantelzell-lymphom"},{"key":"17_CR6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","volume":"367","author":"HC Kluin-Nelemans","year":"2012","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O et al (2012) Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367:520\u2013531","journal-title":"N Engl J Med"},{"key":"17_CR7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203\u20131210","journal-title":"Lancet"},{"key":"17_CR8","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","volume":"31","author":"C Visco","year":"2013","unstructured":"Visco C, Finotto S, Zambello R et al (2013) Combination of rituximab, bendamustine and cytarabine for patients with mantle cell Non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantations. J Clin Oncol 31:1442\u20131449","journal-title":"J Clin Oncol"},{"key":"17_CR9","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E et al (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma \u2013 results of a prospective randomized trial of the european MCL network. Blood 105:2677\u20132684","journal-title":"Blood"},{"issue":"Suppl. 1","key":"17_CR10","first-page":"86","volume":"31","author":"O Hermine","year":"2013","unstructured":"Hermine O, Hoster E, Szymczyk M et al (2013) Alternating courses of 3x CHOP and 3xDHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared with six courses of CHOP plus Rituximab followed by myeloablative radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final analysis of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL NET). Hematol Oncol 31(Suppl. 1):86","journal-title":"Hematol Oncol"},{"key":"17_CR11","first-page":"\u25a0","volume":"Abstract 146","author":"S Gouill Le","year":"2014","unstructured":"Le Gouill S et al (2014) Rituximab maintenance versus wait and watch after four courses of R\u2011DHAP followed by autologous stem cell transplantation in previously untreated young patients with mantle cell lymphoma: first interim analysis of the phase III prospective Lyma trial, a Lysa Study. Am Soc Hematol Abstract 146:","journal-title":"Am Soc Hematol"},{"key":"17_CR12","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/annonc\/mds054","volume":"23","author":"S Gouill Le","year":"2012","unstructured":"Le Gouill S, Kr\u00f6ger N, Dhedin N et al (2012) Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed\/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 23:2695\u20132703","journal-title":"Ann Oncol"},{"issue":"5","key":"17_CR13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bmt.2014.328","volume":"50","author":"AK Zoellner","year":"2015","unstructured":"Zoellner AK, Fritsch S, Prevalsek D et al (2015) Sequential therapy combining clofarabine and T\u2011cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma. Bone Marrow Transplant 50(5):679\u2013684","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"17_CR14","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","volume":"372","author":"T Robak","year":"2015","unstructured":"Robak T, Huang H, Jin J et al (2015) Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 372(10):944\u2013953","journal-title":"N Engl J Med"},{"key":"17_CR15","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J et al (2009) Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:3822\u20133829","journal-title":"J Clin Oncol"},{"key":"17_CR16","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1038\/leu.2015.60","volume":"29","author":"G Hess","year":"2015","unstructured":"Hess G, Keller U, Scholz CW et al (2015) Safety and efficacy of temsirolimus in combination with bendamustine and rituximab in relapsed mantle cell and follicular lymphoma. Leukemia 29:1695\u20131701","journal-title":"Leukemia"},{"key":"17_CR17","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","volume":"22","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Vose JM, Zinzani PL et al (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B\u2011cell non-Hodgkin\u2019s lymphoma. Ann Oncol 22:1622\u20131627","journal-title":"Ann Oncol"},{"key":"17_CR18","first-page":"\u25a0","volume":"Abstract 626","author":"M Trneny","year":"2014","unstructured":"Trneny M et al (2014) Phase II randomized, multicenter study of lenalidomide vs best investigator\u2019s choice in relapsed\/refractory mantle cell lymphoma: results of the MCL-002 (SPRINT) study. Am Soc Hematol Abstract 626:","journal-title":"Am Soc Hematol"},{"issue":"19","key":"17_CR19","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","volume":"373","author":"J Ruan","year":"2015","unstructured":"Ruan J, Martin P, Shah B et al (2015) Lenalidomide plus Rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med 373(19):1835\u20131844","journal-title":"N Engl J Med"},{"key":"17_CR20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P et al (2013) Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507\u2013516","journal-title":"N Engl J Med"},{"key":"17_CR21","first-page":"\u25a0","volume":"\u25a0","author":"M Dreyling","year":"2015","unstructured":"Dreyling M, Jurczak W, Jerkeman M et al (2015) Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet (im Druck)","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"17_CR22","first-page":"207","volume":"33","author":"P Martin","year":"2015","unstructured":"Martin P, Maddocks K, Leonard J et al (2015) Poor overall survival of patients with Ibrutinib-resistant mantle cell lymphoma. Hematol Oncol 33(Suppl. 1):207 (13th International Conference on Malignant Lymphoma, Lugano)","journal-title":"Hematol Oncol"},{"issue":"22","key":"17_CR23","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","volume":"123","author":"BS Kahl","year":"2014","unstructured":"Kahl BS, Spurgeon SE, Furman RR et al (2014) A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL). Blood 123(22):3398\u20133405","journal-title":"Blood"},{"issue":"2007","key":"17_CR24","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","volume":"7","author":"P Jares","year":"2007","unstructured":"Jares P, Colomer D, Campo E (2007) Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 7(2007):750\u2013762","journal-title":"Nat Rev Cancer"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-016-0017-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-016-0017-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-016-0017-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T04:17:44Z","timestamp":1558585064000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-016-0017-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,17]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["17"],"URL":"https:\/\/doi.org\/10.1007\/s00108-016-0017-y","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,17]]}}}